Hybio Pharmaceutical

Hybio Pharmaceutical, established in 1998, is a prominent player in the pharmaceutical and healthcare sectors, specializing in the research and development of peptide and small nucleic acid drugs. The company integrates advanced AI technology to streamline drug discovery and development processes. By maintaining a comprehensive platform that spans the entire industry chain, Hybio Pharmaceutical has achieved significant international milestones, including multiple FDA certifications. Their commitment to innovation ensures the delivery of high-purity active pharmaceutical ingredients and quality formulations that meet rigorous global standards.

Operating with a workforce of 500-1,000 employees, the company maintains a robust operational footprint. Their products are currently distributed across more than 30 countries, reflecting a strong commitment to global market expansion and accessibility. Hybio Pharmaceutical focuses on high-tech manufacturing, producing complex custom peptides and specialized pharmaceutical solutions. By adhering to international quality benchmarks, the firm continues to enhance its production capabilities, ensuring that patients worldwide receive reliable and effective treatment options. The company’s strategic focus remains on scaling its R&D infrastructure to address complex medical needs through precision medicine and advanced biotechnology.

The organizational structure at Hybio Pharmaceutical is designed to support large-scale R&D and manufacturing operations. Meet Hybio Pharmaceutical's team to learn about the leadership and technical experts driving their mission. With a primary location in Wuhan, Hubei, China, the company leverages its centralized expertise to maintain strict quality control across all product lines. Their ongoing investment in human capital and technological infrastructure positions them as a key competitor in the global peptide drug market.